

HEALTHCARE MONTHLY

JULY 2024


Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.

BioTech / Pharma **Healthcare Services** Life Sciences / Diagnostics **Medical Devices**

HEADLINE TRANSACTIONS

ACQUIROR ACQUISITION SYNOPSIS





- · Sharecare is a digital health company helping healthcare organizations communicate with and manage their patient populations
- A L T A R I S Altaris is a private equity firm founded in 2003 and managing ~\$10 billion of equity capital in healthcare-focused companies across pharmaceuticals, medical devices, life sciences & diagnostics and healthcare services
 - Total Consideration: \$596 million cash
 - Per Share Price Premium: 84.7%





- Waste Management, Inc. (NYSE:WM) has entered a definitive agreement to acquire Stericycle (NASD:SRCL)
- · Stericycle, Inc. provides regulated waste and compliance services, including management and disposal of regulated medical waste, sharps waste, pharmaceutical waste, chemotherapy waste and healthcare hazardous waste
- WM is a provider of comprehensive environmental solutions, including collection, recycling and disposal services
- Total Consideration: \$7.2 billion cash
- Per Share Price Premium: 20.3%





- Boston Scientific Corporation (NYSE:BSX) has entered a definitive agreement to acquire Silk Road Medical, Inc. (NASD:SILK)
- · Silk Road Medical is a medical device company developing products to prevent stroke in patients with carotid artery disease
- Boston Scientific provides medical technologies focused on complex cardiovascular, respiratory, digestive, oncological, neurological and urologic diseases and conditions
- Total Consideration: \$1.2 billion cash
- Per Share Price Premium: 26.9%






- Johnson & Johnson (NYSE:JNJ) has completed the acquisition of Proteologix, Inc.
- · Proteologix is a pre-clinical stage biotechnology company focused on bispecific antibodies for immune-mediated diseases, including atopic dermatitis and asthma
- Johnson & Johnson researches, develops, manufactures and sells products in numerous healthcare segments including consumer health, pharmaceutical and medtech
- Total Consideration: \$850 million cash




HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins*



*EBITDA Margins shown as the gray line.

LTM Stock Price Index





SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
Celsius Therapeutics, Inc.	AbbVie, Inc. (NYSE:ABBV)	Celsius Therapeutics is a clinical-stage biotechnology company developing new therapies for inflammatory diseases including inflammatory bowel disease Total Consideration: \$250 million cash
Searchlight Pharma, Inc.	Apotex, Inc.	Searchlight is a Canadian specialty branded pharmaceutical company focusing on women's health, dermatology, allergy, pain management and hospital specialty markets
Alimera Sciences (NASD:ALIM)	Ani Pharmaceuticals, Inc. (NASD:ANIP)	Alimera is a global pharmaceutical company developing commercial products to treat diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment of the eye Total Consideration: \$327 million cash Per Share Price Premium: 90.5%
Target	Acquiror	Life Sci / Diagnostics Transactions
DCS Innovative Diagnostik- Systeme GmbH & Co. KG	Acquiror Calibre Scientific, Inc. (StoneCalibre, LLC)	DCS supplies reagents and equipment used in immunohistochemistry for the diagnostic, research, industrial, university and hospital industries, with a focus on clinical pathology and oncology
DCS Innovative Diagnostik- Systeme GmbH &	Calibre Scientific, Inc. (StoneCalibre,	DCS supplies reagents and equipment used in immunohistochemistry for the diagnostic, research, industrial, university and hospital industries, with a

Selected TM Capital Healthcare Experience









TM Capital's Healthcare Industry Contacts



James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



Michael Goldman Managing Director mgoldman@tmcapital.com 212.809.1419



John Dean Director jdean@tmcapital.com 404.995.6234



Paul Smolevitz
Managing Director
psmolevitz@tmcapital.com
212.809.1416



Josh Mastracci Director jmastracci@tmcapital.com 404.924.4562



Steve Hunter Managing Director, Sponsor Coverage shunter@tmcapital.com 404.995.6232

